Gsa Capital Partners LLP Bio Atla, Inc. Transaction History
Gsa Capital Partners LLP
- $1.11 Billion
- Q1 2025
A detailed history of Gsa Capital Partners LLP transactions in Bio Atla, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 233,156 shares of BCAB stock, worth $86,267. This represents 0.01% of its overall portfolio holdings.
Number of Shares
233,156
Previous 350,731
33.52%
Holding current value
$86,267
Previous $207,000
60.87%
% of portfolio
0.01%
Previous 0.02%
Shares
6 transactions
Others Institutions Holding BCAB
# of Institutions
46Shares Held
13.9MCall Options Held
20.3KPut Options Held
1.2K-
Acorn Capital Advisors, LLC New York, NY4.03MShares$1.49 Million0.98% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.82MShares$672,6600.0% of portfolio
-
Acadian Asset Management LLC Boston, MA1.69MShares$625,3400.0% of portfolio
-
Tang Capital Management LLC San Diego, CA1.37MShares$508,4080.03% of portfolio
-
Black Rock Inc. New York, NY792KShares$292,8770.0% of portfolio
About BioAtla, Inc.
- Ticker BCAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,304,100
- Market Cap $13.4M
- Description
- BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...